Revenue segments as reported by the company.

Grant revenue

Clinical trial revenue

Contract revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

General and administrative

Research and development

Selling and marketing

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Longeveron

Longeveron, Inc. is a clinical stage biotechnology company. It engages in the development of cellular therapies for specific aging-related and life-threatening conditions. Its lead product, LOMECEL-B, is a cell-based therapy product, which is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young, healthy, adult donors. The company was founded by Joshua M. Hare and Donald M. Soffers on October 9, 2014 and is headquartered in Miami, FL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Longeveron reports promising Q1 results, secures funding for growth

Longeveron's Q1 2024 earnings call highlighted positive Phase I results for HLHS and cost management efforts. The company secured funding for further development and welcomed new board members. Challenges include regulatory hurdles and market competition, but opportunities lie in expanding therapeutic applications and revenue growth potential.

Longeveron reports positive Q2 results, eyes contract services expansion

Longeveron's Q2 2024 earnings call highlighted strong performance in trials and financials, with a focus on HLHS program advancement and contract services expansion. The company faces challenges in addressing analyst inquiries and maximizing its contract services business potential, but has opportunities for revenue growth and leveraging positive trial outcomes.

Longeveron reports robust revenue growth and progresses towards FDA approval

Longeveron's Q3 2024 performance reflects strong revenue growth and advancements in regulatory pathways for their product candidate, Lomecel-B, across multiple therapeutic areas.
The company's focus on cellular therapies aligns with a lucrative market potential in the U.S., but funding needs for accelerated activities and competitive challenges pose considerations for future strategies.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Longeveron, Inc. is a clinical stage biotechnology company, which engages in the development of cellular therapies for specific aging-related and life-threatening conditions. Its lead product, LOMECEL-B, is a cell-based therapy product, which is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young, healthy, adult donors. The company was founded by Joshua M. Hare and Donald M. Soffer on October 9, 2014 and is headquartered in Miami, FL.

ELPIS II Study Exceeds 50% Enrollment Threshold for Phase 2 Trial of Lomecel-B™  in HLHS Top Line Results for CLEAR MIND Alzheimer's disease Phase 2a Trial Anticipated by October 2023 Company Strengthens Leadership Team and Board of Directors with Distinguished New Additions Company to Hold Conference Call and Webcast Today, August 11, 2023 at 8am Eastern Time MIAMI, Aug. 11, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, announced today its results for the quarter ended June 30, 2023 and provided a corporate update. “During our second quarter and in recent weeks, we made significant progress advancing our Lomecel-B™ clinical programs, exceeding the 50% enrollment threshold for our ELPIS II trial in hypoplastic left heart syndrome (HLHS) patients and announcing new long-term survival data from our ELPIS I study,” said Wa'el Hashad, Chief Executive Officer of Longeveron.

Longeveron Reports Second Quarter 2023 Results and Provides Corporate Update

Company Activates Additional Study Location to Expedite Enrollment Completion Key Opinion Leader Webinar Highlighting the Potential for Lomecel-B™  in the Treatment of HLHS to be held Wednesday, August 16, 2023 at 10:00 AM ET MIAMI, Aug. 11, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, announced today the Phase 2 ELPIS II trial, funded by the National Heart, Lung, and Blood Institute (NHLBI) and using the Company's Lomecel-B™ asset in Hypoplastic Left Heart Syndrome (HLHS), has surpassed the 50% enrollment threshold. Additionally, the trial has activated its eighth clinical site location – one additional site beyond the seven originally planned -- in order to try to expedite the completion of the trial enrollment.

Longeveron Announces Achievement of Surpassing 50% Enrollment Threshold in Phase 2 ELPIS II Study of Lomecel-B™ in Hypoplastic Left Heart Syndrome

MIAMI, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, announced today that it will report its second quarter 2023 financial results prior to the market open on Friday, August 11, 2023. The Company will host a conference call and webcast that day to discuss the results, provide an update on its clinical programs and corporate activities. A question-and-answer session will follow the prepared remarks.

Longeveron to Report Second Quarter 2023 Results and Provide Corporate Update on August 11, 2023

MIAMI, July 20, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, announced today the appointment of Lisa Locklear as Executive Vice President and Chief Financial Officer. Ms. Locklear is an accomplished leader with global business experience, and is a respected finance professional in the biopharmaceutical industry. The appointment is effective as of July 31, 2023.

Longeveron Appoints Lisa Locklear as Chief Financial Officer

Experienced Pharma Industry Clinical Operations Leader to Spearhead Development of Cellular Therapy Programs Experienced Pharma Industry Clinical Operations Leader to Spearhead Development of Cellular Therapy Programs

Longeveron Appoints Dr. Nataliya Agafonova as Chief Medical Officer

MIAMI, July 10, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, announced today that Chairman, Co-founder and Chief Science Officer Joshua Hare, MD, FACC, has been inducted as a fellow of the prestigious National Academy of Inventors (NAI) in recognition of his leading-edge research and development of stem cell therapies for heart disease. Dr. Hare was officially inducted into NAI on June 27, 2023, at the Academy's annual meeting in Washington, D.C.

Longeveron Congratulates Co-Founder and Chairman Dr. Joshua Hare on Induction as Fellow of National Academy of Inventors

MIAMI, June 27, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as Alzheimer's Disease and Aging Frailty, announced today that it has filed a registration statement with the Securities and Exchange Commission (“SEC”) to conduct a tradeable subscription rights offering to its shareholders and holders of warrants to purchase common stock as of a future record date to be determined.

Longeveron Files Registration Statement for Rights Offering

Seasoned Biotechnology and Corporate Management Experts, Khoso Baluch, Jeffrey Pfeffer, and Wa'el Hashad, Elected to Board at Annual Meeting of Stockholders

Longeveron Welcomes Three New Prominent Board Members

Longeveron Inc. (NASDAQ:LGVN ) Q1 2023 Earnings Conference Call May 12, 2023 8:30 AM ET Company Participants James Clavijo - Chief Financial Officer Wa'el Hashad - Chief Executive Officer Chris Min - Acting Chief Medical Officer & Consultant Conference Call Participants Michael Okunewitch - Maxim Group Operator Good morning, and welcome to Longeveron's call today to discuss the company's 2023 First Quarter and Financial Results. All participants are currently in listen-only mode.

Longeveron Inc. (LGVN) Q1 2023 Earnings Call Transcript

Longeveron (NASDAQ: LGVN ) just reported results for the first quarter of 2023. Longeveron reported a loss per share of 22 cents.

LGVN Stock Earnings: Longeveron Misses EPS, Revenue Estimates

-- New long-term survival data disclosed from ELPIS I trial of Lomecel-B TM for Hypoplastic Left Heart Syndrome; Data reinforce potential mortality benefit -- -- First patient dosed in Phase 2 clinical trial of Lomecel-B TM for Aging-Related Frailty in Japan --

Longeveron Inc. Provides Corporate Update and Reports First Quarter 2023 Financial Results

Longeveron (NASDAQ: LGVN ) stock is on the move Tuesday after releasing long-term survival data from its HLHS treatment. According to the company, all 10 patients that received Lomecel-B during their stage 2 surgery are still alive after up to five years.

Why Is Longeveron (LGVN) Stock Up 30% Today?

Longeveron Inc.'s stock LGVN rocketed 15.5% in premarket trade Tuesday, after the biotech said its Lomecel-B for the treatment of a congenital heart defect in infants (Hypoplastic Left Heart Syndrome) achieved 100% survival up to 5 years of age in a trial. The trial involved 10 patients who survived and remained transplant-free after receiving Lomecel-B during Stage 2 surgery.

Longeveron stock up 15.5% premarket after positive results in trial of treatment for rare congenital heart defect in infants

- Children in the ELPIS I trial had 100% survival up to 5 years of age after receiving Lomecel-B TM compared to 20% mortality rate observed from historical control data -

Longeveron Announces New Long-Term Survival Data from ELPIS I Trial of Lomecel-B™ for Hypoplastic Left Heart Syndrome

MIAMI, May 08, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, today announced that the Company will release its first quarter 2023 financial results on Friday, May 12, 2023 before the open of the U.S. financial markets. Management will host a conference call to discuss the Company's financial results and provide a corporate update on the same day at 8:30 a.m.

Longeveron to Announce First Quarter 2023 Financial Results on May 12, 2023

-- The study's primary objective is to evaluate the safety of Lomecel-B™  in Japan's elderly population -- -- First-in-human clinical trial of Lomecel-B™  in Japan --

Longeveron Announces First Patient Dosed in Phase 2 Clinical Trial of Lomecel-B™ for Aging-Related Frailty in Japan

Longeveron Inc. (NASDAQ:LGVN ) Q4 2022 Results Conference Call March 10, 2023 8:30 AM ET Company Participants James Clavijo - CFO Wa'el Hashad - CEO Dr. Chris Min - Chief Medical Officer Conference Call Participants Michael Okunewitch - Maxim Group Operator Good morning, and welcome to Longeveron's call today to discuss the company's 2022 Fourth Quarter and Full Year Financial Results. [Operator Instructions] I would now like to turn the call over to James Clavijo, Longeveron's Chief Financial Officer.

Longeveron Inc. (LGVN) Q4 2022 Earnings Call Transcript

-- Full results from ELPIS I trial published in European Heart Journal Open –

Longeveron Inc. Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results

Live conference call on Friday, March 10 at 8:30 a.m. ET Live conference call on Friday, March 10 at 8:30 a.m. ET

Longeveron to Announce Fourth Quarter and Full Year Financial Results on March 10, 2023

Hashad is a former executive at Avanir, Amgen, Boehringer Ingelheim, Eli Lilly, and early-stage biotechnology companies

Longeveron Appoints Wa'el Hashad as Chief Executive Officer

-- Full results published in European Heart Journal Open -- -- Study met primary safety endpoint --

Longeveron Announces Publication of Final Data from ELPIS I Trial of Lomecel-BTM for Hypoplastic Left Heart Syndrome in Peer-Reviewed Journal

Enservco

Rapid7

In November 2021, I made an outlandish effort to pick 5 cheap stocks that could double within a month. Few companies rise 100%, and even fewer can do it in the time it takes to properly pickle a cucumber.

3 Penny Stocks That Could Rise 500% in 2023

– Expects to enroll first patient in Phase 2  clinical trial of Lomecel-B™ for Aging-Related Frailty in Japan in 1Q23 –

UPDATE -- Longeveron Provides Corporate Update and Announces 2023 Strategic Priorities and Anticipated Milestones

Longeveron Provides Corporate Update and Announces 2023 Strategic Priorities and Anticipated Milestones

MIAMI, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, today announced that Company leadership will participate in three upcoming investor conferences.

News for Longeveron Stock (LGVN)